

To: **Indira IVF Hospital Pvt.Ltd-Hubli**  
First And Second Floor, Ward No.1 Sir Siddha Park,  
Kambli Road, Lamington Rd,  
Karnataka  
Hubli - 580020  
Contact:  
**Report Of: Mrs. MANJULA MOTAGI**  
Pt. Contact: 9035152013



Sample ID 2310023223  
Patient ID 110235618  
Hospital ID UBL0001106  
Received on 22/05/2023 13:57  
Registered on 23/05/2023 11:05  
Reported on -  
Referred by **DR.ASHA PATIL**  
Sonography by **DR.SHILPA GOKAVI**

Understand Your  
Report In Detail



Scan QR code

**EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT**

**Patient Name: Mrs. MANJULA MOTAGI**

**Patient DOB: 06/06/1995**

**Sample Type: Serum**

**Collection Date: 19/05/2023**

**Method: Electrochemiluminescence ( Roche )**

**EVIC**Screen™ is an evidence based prenatal screening program curated by Lilac Insights in accordance with the Fetal Medicine Foundation (UK) guidelines for First Trimester Screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 7 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies

**UKNEQAS: United Kingdom National External Quality Assessment Service**

The Risk Assessment Performed Using  
CE-Marked Antenatal Risk Evaluation Software  
Certified by the British Standards Institute  
(BSI)- ISO 13485:2016

**RIQAS: Randox International Quality Assessment Scheme**



Test Name	Result.	Units
Free-β-hCG	39.59	ng/mL
PAPP-A	7591.00	mIU/L

**Note**

1. Values mentioned above are observed values for PAPP-A & Free β-hCG in the pregnancy on the day of sample collection. These values should not be interpreted in isolation and need to be necessarily incorporated in a validated prenatal Aneuploidy risk calculation software, along with ultrasound and biophysical parameters to calculate the patients individualised risk for aneuploidies like T21, T18, T13 and interpreted accordingly.
2. Biochemical analysis have been performed in accordance to the Fetal Medicine Foundation (FMF) UK guidelines. External QC performed by United Kingdom National External Quality Assessment Service (UKNEQAS). We will appreciate you providing us the outcomes.
3. Divide the values for PAPP-A by 1000 for ASTRAIA Software.



**UK NEQAS**  
International Quality Expertise  
Lab Reg. No. 90968

Verified by  
**Mr. Pradip Kadam**  
Incharge Biochemistry

Verified by  
**Dr. Suresh Bhanushali**  
MD (Path), Consultant Pathologist